KIORA PHARMACEUTICALS INC 8-K

What Happened
Kiora Pharmaceuticals, Inc. (KPRX) filed a Form 8-K reporting that Eric J. Daniels, M.D., MBA, notified the company on April 1, 2026 that he will resign as Chief Development Officer effective April 17, 2026 to pursue another opportunity. The company issued a press release about the resignation on April 2, 2026.

Key Details

• Resignation letter received April 1, 2026; effective date April 17, 2026.
• Officer: Eric J. Daniels, M.D., MBA — Chief Development Officer.
• Company disclosed the change under Item 5.02 (departure of certain officers) and furnished a press release under Item 7.01 (Regulation FD Disclosure) as Exhibit 99.1.
• Filing signed by Melissa Tosca, Chief Financial Officer, on April 2, 2026; the press release is furnished but not “filed” for Section 18 liability purposes.

Why It Matters
A change in the senior development lead can affect oversight of Kiora’s clinical and development programs; investors should note the timeline and watch for announcements about an interim or permanent replacement and any related updates to program milestones or guidance. The filing states the resignation was to pursue another opportunity and was not due to any disagreement with the company’s operations, policies, or practices.